PT  - JOURNAL ARTICLE
AU  - Hind A. Alnajashi
AU  - Foziah J. Alshamrani
AU  - Mark S. Freedman
TI  - Tolerability and discontinuation rates in teriflunomide-treated patients
AID  - 10.17712/nsj.2018.3.20180003
DP  - 2018 Jul 01
TA  - Neurosciences Journal
PG  - 204--207
VI  - 23
IP  - 3
4099  - http://nsj.org.sa/content/23/3/204.short
4100  - http://nsj.org.sa/content/23/3/204.full
SO  - Neurosciences (Riyadh)2018 Jul 01; 23
AB  - Objectives: To assess the real-world tolerability of teriflunomide in multiple sclerosis (MS) patients from a large Canadian MS Centre of Care to determine whether previously treated (PT) patients have different tolerability thresholds than treatment-naive (TN) patients, leading to differing discontinuation rates.Methods: This non-interventional, single-center, retrospective chart review examined all patients who were prescribed commercial teriflunomide between July 2014 and May 2015 at the MS Clinic in the Ottawa General Hospital and Research Institute, Ottawa, Canada.Results: A total of 119 patient charts were reviewed (29 TN and 90 PT). Overall, 19 (15.9%) patients discontinued teriflunomide after a mean treatment duration of 35 weeks. The most common reason for discontinuation was side effects in 8 patients (42%).Discontinuation due to intolerability alone occurred in 13 patients. The number of discontinuations was not sufficient to demonstrate a statistically significant difference between TN and PT patients (p=0.1).Conclusions: This retrospective chart review provides some evidence about the real-world tolerability of teriflunomide. Discontinuations were low overall and consistent with previously reported clinical trial data. There was no significant difference in discontinuation rates between patients in the TN and PT groups. We believe that teriflunomide is a safe and well-tolerated oral alternative to injectable therapies.